References
- WHO. Respiratory syncytial virus (RSV) disease. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/respiratory-syncytial-virus-disease.
- Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543–7. doi:10.1001/archpedi.1986.02140200053026.
- Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, Campbell H, Demont, Nyawanda BO, Chu HY, et al. Global disease burden estimates of respiratory syncytial virus–associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222(S7):S577–83. doi:10.1093/infdis/jiz059.
- Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, Allen J, Falsey A, Pirçon J-Y, Gruselle O, et al. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (Resceu): an international prospective cohort study. Eur Respir J. 2021;57(4):2002688. doi:10.1183/13993003.02688-2020.
- Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018 Oct;18(10):295–311. doi:10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18.
- FDA. Abrysvo® package insert. https://www.fda.gov/vaccines-blood-biologics/abrysvo.
- FDA. Arexvy® package insert. https://www.fda.gov/vaccines-blood-biologics/arexvy.
- Williams K, Bastian AR, Feldman RA, Omoruyi E, De Paepe E, Hendriks J, van Zeeburg H, Godeaux O, Langedijk JPM, Schuitemaker H, et al. Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged ≥60years. J Infect Dis. 2020;222(6):979–88. doi:10.1093/infdis/jiaa193.
- Sadoff J, De Paepe E, DeVincenzo J, Gymnopoulou E, Menten J, Murray B, Bastian AR, Vandebosch A, Haazen W, Noulin N, et al. Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study. J Infect Dis. 2021 Jan 5;226:396–406. doi:10.1093/infdis/jiab003. Epub ahead of print. PMID: 33400792.
- Saeland E, Van der Fits L, Bolder R, Heemskerk-van der Meer M, Drijver J, Van Polanen Y, Vaneman C, Tettero L, Serroyen J, Schuitemaker H, et al. Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models. NPJ Vaccines. 2023;8:45. doi:10.1038/s41541-023-00637-7.
- Comeaux C, Bart S, Bastian AR, Klyashtornyy V, De Paepe E, Omoruyi E, Van der Fits L, Van Heesbeen R, Heijnen E, Callendret B, et al. Safety, immunogenicity, and regimen selection of Ad26.RSV.preF–based vaccine combinations: a randomized, double-blind, placebo-controlled, phase 1/2a study. J Infect Dis. 2023;229:19–29. doi:10.1093/infdis/jiad220.
- Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, Menten J, De Paepe E, Vandenberghe S, Chan EKH, et al. Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults. N Engl J Med. 2023;388:609–20. doi:10.1056/NEJMoa2207566.
- WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations; 2017. WHO technical report series 1004, annex 9. https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9.
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. doi:10.1001/jama.2013.281053.
- US Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials; 2007. https://www.fda.gov/media/73679/download.
- Brighton Collaboration. Interim case definition of thrombosis with thrombocytopenia syndrome (TTS); 2021. https://brightoncollaboration.us/thrombosis-with-thrombocytopenia-syndrome-interim-case-definition/.
- ACIP. Update: Thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination 2021; updated 2021 May 12. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/07-COVID-Shimabukuro-508.pdf.
- NICE. Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19; 2020. https://www.nice.org.uk/guidance/NG188.
- ICH Q6B. Guidelines. https://www.ich.org/page/quality-guidelines.